Literature DB >> 3108325

Opsonisation and phagocytosis of group B meningococci by polymorphonuclear leucocytes: comparison of sulphonamide sensitive and resistant strains.

K N Ward, A Fleer, J Verhoef, D M Jones.   

Abstract

A large proportion of disease caused by sulphonamide resistant strains of group B type 15 meningococci affects patients 10-24 years. In contrast, disease caused by sulphonamide sensitive strains conforms to the usual pattern, and most infection occurs in early childhood. In an attempt to explain this phenomenon possible differences in susceptibility of resistant and sensitive strains to phagocytosis by polymorphonuclear leucocytes were investigated, using radioactively labelled bacteria. In initial experiments a group B resistant strain required higher concentrations of normal human serum and longer opsonisation times for phagocytosis than an ungroupable non-pathogenic meningococcus. Comparison of sulphonamide resistant and sensitive group B meningococci showed that with either heat inactivated serum or agammaglobulinaemic serum, phagocytosis did not occur with any of the strains, whereas if these two sera were used together, phagocytosis was restored to the level seen with normal human serum. Thus both antibody and complement are required for phagocytosis. Furthermore, opsonisation depended on an intact classical pathway of complement for each group B strain. In all the experiments there was no significant difference between the phagocytosis of sulphonamide sensitive and resistant group B strains neither with regard to the efficiency of opsonisation by normal human serum nor the exact requirements for antibody and complement.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3108325      PMCID: PMC1140964          DOI: 10.1136/jcp.40.4.361

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  18 in total

1.  Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV.

Authors:  G S Giebink; J Verhoef; P K Peterson; P G Quie
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

2.  Risk factors in bacterial meningitis: Charleston County, South Carolina.

Authors:  D W Fraser; C P Darby; R E Koehler; C F Jacobs; R A Feldman
Journal:  J Infect Dis       Date:  1973-03       Impact factor: 5.226

3.  Kinetics of staphylococcal opsonization, attachment, ingestion and killing by human polymorphonuclear leukocytes: a quantitative assay using [3H]thymidine labeled bacteria.

Authors:  J Verhoef; P K Peterson; P G Quie
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

4.  The use of protein A-containing staphylococci sensitized with anti-meningococcal antibodies for grouping Neisseria meningitidis and demonstration of meningococcal antigen in cerebrospinal fluid.

Authors:  P Olcén; D Danielsson; J Kjellander
Journal:  Acta Pathol Microbiol Scand B       Date:  1975-08

5.  Human heat labile opsonins: evidence for their mediation via the alternate pathway of complement activation.

Authors:  H E Jasin
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

6.  The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man.

Authors:  R B Roberts
Journal:  J Exp Med       Date:  1970-03-01       Impact factor: 14.307

7.  Group B meningococcal opsonins in serum measured by polymorphonuclear leukocyte chemiluminescence.

Authors:  V Lehmann; C O Solberg
Journal:  Acta Pathol Microbiol Scand C       Date:  1980-08

8.  The opsonic fragment of the third component of human complement (C3).

Authors:  T P Stossel; R J Field; J D Gitlin; C A Alper; F S Rosen
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

9.  The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors.

Authors:  R B Johnston; M R Klemperer; C A Alper; F S Rosen
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  2 in total

1.  Cross-reacting serum opsonins in patients with meningococcal disease.

Authors:  H K Guttormsen; R Bjerknes; A Naess; V Lehmann; A Halstensen; S Sørnes; C O Solberg
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

Review 2.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.